• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer.前列腺特异性抗原(PSA)筛查前列腺癌:对高度侵袭性前列腺癌患者的获益。
Asian J Androl. 2013 Mar;15(2):218-20. doi: 10.1038/aja.2012.130. Epub 2013 Jan 21.
2
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.美国预防服务工作组“D”级推荐对前列腺癌筛查及分期的影响
Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383.
3
Prostate Cancer Screening.前列腺癌筛查
Med Clin North Am. 2018 Mar;102(2):199-214. doi: 10.1016/j.mcna.2017.11.001.
4
PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.美国预防服务工作组建议反对前列腺癌筛查后,对前列腺特异性抗原筛查、前列腺活检和前列腺癌治疗的相关情况。
Cancer. 2018 Jul 1;124(13):2733-2739. doi: 10.1002/cncr.31337. Epub 2018 May 21.
5
Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.在根治性前列腺切除标本中,四种激肽释放酶标志物对与侵袭性前列腺癌相比病理意义不显著的前列腺癌的预测价值:来自欧洲前列腺癌筛查随机研究鹿特丹分部的结果
Eur Urol. 2013 Nov;64(5):693-9. doi: 10.1016/j.eururo.2013.04.040. Epub 2013 May 2.
6
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.美国与欧洲前列腺癌筛查随机研究-鹿特丹的前列腺特异性抗原筛查比较。
J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.
7
Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.前列腺特异性抗原(PSA)筛查试验和修订的 PSA 筛查指南对前列腺活检率和活检后并发症的影响。
Eur Urol. 2017 Jan;71(1):55-65. doi: 10.1016/j.eururo.2016.03.015. Epub 2016 Mar 16.
8
Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.前列腺特异性抗原密度与病理性显著前列腺癌的关系:前列腺体积的影响。
Prostate. 2020 Dec;80(16):1444-1449. doi: 10.1002/pros.24078. Epub 2020 Sep 24.
9
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.中年时期前列腺特异性抗原水平与黑人男性侵袭性前列腺癌。
Eur Urol. 2019 Mar;75(3):399-407. doi: 10.1016/j.eururo.2018.08.032. Epub 2018 Sep 17.
10
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.前列腺癌筛查:美国预防服务工作组推荐声明。
JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.

引用本文的文献

1
Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score.使用前列腺特异性抗原和 Gleason 评分的前列腺癌根治术后生化复发风险预测模型。
Asian J Androl. 2014 Nov-Dec;16(6):897-901. doi: 10.4103/1008-682X.129940.

本文引用的文献

1
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.前列腺癌筛查:美国预防服务工作组推荐声明。
Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.
2
Prostate-cancer mortality at 11 years of follow-up.前列腺癌死亡率随访 11 年后。
N Engl J Med. 2012 Mar 15;366(11):981-90. doi: 10.1056/NEJMoa1113135.
3
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial.在一项欧洲随机试验中,前列腺活检后的感染并发症和住院治疗。
Eur Urol. 2012 Jun;61(6):1110-4. doi: 10.1016/j.eururo.2011.12.058. Epub 2012 Jan 5.
4
[Prevention of complications of general anesthesia linked with laparoscopic access and with robot-assisted radical prostatectomy].[预防与腹腔镜入路及机器人辅助根治性前列腺切除术相关的全身麻醉并发症]
Prog Urol. 2011 Nov;21(12):829-34. doi: 10.1016/j.purol.2011.05.004. Epub 2011 Sep 3.
5
Radical retropubic prostatectomy: a review of outcomes and side-effects.根治性耻骨后前列腺切除术:疗效和副作用的回顾。
Acta Oncol. 2011 Jun;50 Suppl 1:92-7. doi: 10.3109/0284186X.2010.535848.
6
Prostate-specific antigen (PSA) screening: has the pendulum swung too far?前列腺特异性抗原(PSA)筛查:钟摆是否摆得太远了?
Asian J Androl. 2011 Sep;13(5):655-6. doi: 10.1038/aja.2011.49. Epub 2011 May 23.
7
Steps in prostate cancer progression that lead to bone metastasis.导致前列腺癌骨转移的进展步骤。
Int J Cancer. 2011 Jun 1;128(11):2545-61. doi: 10.1002/ijc.26024. Epub 2011 Mar 28.
8
Randomized studies of PSA screening: an opinion.前列腺特异性抗原(PSA)筛查的随机研究:一种观点。
Asian J Androl. 2011 May;13(3):364-5. doi: 10.1038/aja.2011.12. Epub 2011 Feb 28.
9
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.2008 年全球癌症负担估计值:GLOBOCAN 2008。
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
10
Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening.美国 2010 年癌症筛查:对现行美国癌症协会指南的回顾以及癌症筛查中的问题。
CA Cancer J Clin. 2010 Mar-Apr;60(2):99-119. doi: 10.3322/caac.20063.

前列腺特异性抗原(PSA)筛查前列腺癌:对高度侵袭性前列腺癌患者的获益。

Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer.

机构信息

Department of Pathophysiology, Jilin University, Changchun, China.

出版信息

Asian J Androl. 2013 Mar;15(2):218-20. doi: 10.1038/aja.2012.130. Epub 2013 Jan 21.

DOI:10.1038/aja.2012.130
PMID:23334201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3739147/
Abstract

The PSA screening for 25 years in America is the biggest cohort study in a field of public health.27 We should realize not only the significance of the early diagnosis and treatment of PCa, but also the dramatic decrease in PCaMR from 2002 to 2008. The data from the IARC were especially noteworthy.Moreover, the patients with highly aggressive PCa, who account for more than 30% of all PCa patients, could only be diagnosed earlier by PSA screening. The patients would thus gain the opportunity for earlier treatment and would have a prolonged, higher quality life-span. However, the complications of interventional treatments, including biopsy,radical prostatectomy and/or radiation therapy,will become more avoidable in the near future.According to the supporting evidence for the decrease in PCa mortality in PSA screening, we strongly hope that the USPSTF changes the 'D' recommendation for PSA screening.

摘要

美国开展了长达 25 年的 PSA 筛查,这是公共卫生领域最大的队列研究。27 我们不仅应该认识到 PCa 早期诊断和治疗的重要意义,还应该认识到 2002 年至 2008 年期间 PCaMR 的显著下降。国际癌症研究机构的数据尤其值得关注。此外,超过 30%的所有前列腺癌患者都患有高度侵袭性前列腺癌,只有通过 PSA 筛查才能更早地诊断出来。这样,患者就有机会更早地接受治疗,并延长高质量的寿命。然而,包括活检、根治性前列腺切除术和/或放射治疗在内的介入治疗的并发症在不久的将来将变得更加可以避免。根据 PSA 筛查降低前列腺癌死亡率的支持证据,我们强烈希望 USPSTF 改变 PSA 筛查的“D”级推荐。